GLPG: Multiplikator rega marang pendapatan Galapagos N.V.
Geopolitical instability and sanctions are hindering global clinical trials for new drugs, a trend reflected in the price action of Galapagos NV (GLPG). The EV/Revenue multiple clearly demonstrates the current market valuation, with the latest reading standing at 1.40. Business resilience is supported by the diversification of European plants, while the strategic focus is shifting toward decentralized CAR-T therapy production for oncology clinics.
Rincian metrik lan analitis perusahaan Galapagos Genomics (GLPG)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- data kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Total Utang marang Modal Galapagos NV|GLPG - Utang jangka dawa marang ekuitas|Kewajiban jangka cendhak marang ekuitas Galapagos Corp|GLPG - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Galapagos Genomics|GLPG - Utang jangka dawa perusahaan|Tanggungan jangka cendhak Galapagos|Likuiditas darurat glpg.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
GLPG - Bathi resik perusahaan|Prakiraan bathi perusahaan Galapagos NV|GLPG - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Galapagos N.V.|GLPG - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Galapagos Genomics|GLPG - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Galapagos|GLPG - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham sajroning taun lumaku glpg.com|GLPG - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Galapagos NV
- data total pendapatan lan volume dodolan:
Analisis umum perusahaan:GLPG glpg.com
To filter for fundamentally resilient assets, investors compare market capitalization against actual cash flows from sales. This ratio determines the cost per unit of revenue, which is critical for Galapagos NV (GLPG), as the company delegates production and research to contractors to reduce capital expenditures; consequently, the P/S trajectory allows for an objective assessment of the efficiency of this outsourcing model relative to the market price.
Perusahaan pesaing
HLN (haleon.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S KVUE (Kenvue)|Multiplikator rega marang pendapatan Verona Pharma PLC|Jyong Biotech Corp - Multiplikator P/S|LGND - Multiplikator P/S|Amneal Pharmaceuticals (AMRX) - Rasio rega marang pendapatan|PRGO (perrigo.com) - Rasio rega marang pendapatan|ALVO (Alvotech SA) - Multiplikator P/S|Multiplikator P/S Liquidia Corp|Rasio rega marang pendapatan ANI Pharma (ANIP)|MNKD: Rasio rega marang dodolan|Multiplikator P/S AMPH (Amphastar Pharmaceuticals)|Multiplikator P/S pacira.com PCRX|ARS Pharmaceuticals, Inc. - Multiplikator P/S|Multiplikator rega marang pendapatan Theravance Biopharma Inc (TBPH)|Aquestive Pharma (AQST) - Rasio rega marang pendapatan|Rega marang dodolan scPharmaceuticals (SCPH)|Rasio rega marang pendapatan Tectonic Therapeutic Inc.|tonixpharma.com (TNXP) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan SXTC (China SXT Pharmaceuticals)|EPRX (eupraxiapharma.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan BioHarvest BHST|EXOZ: Rasio kapitalisasi marang pendapatan|ORMP: Kapitalisasi marang pendapatan|ENTX: Rasio rega marang pendapatan|HYFT: Multiplikator P/S|Multiplikator rega marang pendapatan ABVC BioPharma Inc. ABVC|Rasio rega marang pendapatan Cumberland Pharma|Rasio rega marang pendapatan QNTM|Rasio rega marang pendapatan FibroGen, Inc. (FGEN)|TELO: Rasio rega marang dodolan|Multiplikator P/S RANI (Rani Therapeutics Holdings, Inc.)|Multiplikator rega marang pendapatan Synergy CHC Corp.|RLYB - Rasio rega marang pendapatan|Rasio rega marang dodolan LEXX|PULM: Multiplikator P/S|Pheton Holdings - Rasio kapitalisasi pasar marang pendapatan|APM (Aptorum Group Ltd) - Multiplikator P/S|Multiplikator P/S Lyra Therapeutics Inc.|Rasio rega marang pendapatan Impact BioMedical (IBO)|TNFA (tnfpharma.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan cbdMD YCBD|PRFX - Kapitalisasi marang pendapatan|Auris Medical - Multiplikator P/S|LIPO - Multiplikator P/S|OPTN (Optinose) - Kapitalisasi marang pendapatan|Pieris Pharma - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Procaps Group S.A.|Rega marang dodolan petrospharma.com PTPI|Kapitalisasi marang pendapatan QLI (Qilian International Holding)|Kapitalisasi marang volume dodolan SLRN|Multiplikator P/S TFFP (TFF Pharma)
